Literature DB >> 11985512

Immunological and pathological comparative analysis between experimental latent tuberculous infection and progressive pulmonary tuberculosis.

A K Arriaga1, E H Orozco, L D Aguilar, G A W Rook, R Hernández Pando.   

Abstract

Mycobacterium tuberculosis produces latent infection or progressive disease. Indeed, latent infection is more common since it occurs in one-third of the world's population. We showed previously, using human material with latent tuberculosis, that mycobacterial DNA can be detected by in situ PCR in a variety of cell types in histologically-normal lung. We therefore sought to establish an experimental model in which this phenomenon could be studied in detail. We report here the establishment of such a model in C57Bl/6 x DBA/2 F1 hybrid mice by the intratracheal injection of low numbers of virulent mycobacteria (4000). Latent infection was characterized by low and stable bacillary counts without death of animals. Histological and immunological study showed granulomas and small patches of alveolitis, with high expression of tumour necrosis factor alpha (TNFalpha), inducible nitiric oxide synthase (iNOS), interleukin 2 (IL-2) and interferon gamma (IFNgamma). In contrast, the intratracheal instillation of high numbers of bacteria (1 x 106) produced progressive disease. These animals started to die after 2 months of infection, with very high bacillary loads, massive pneumonia, falling expression of TNF-alpha and iNOS, and a mixed Th1/Th2 cytokine pattern. In situ PCR to detect mycobacterial DNA revealed that the most common positive cells in latently-infected mice were alveolar and interstitial macrophages located in tuberculous lesions, but, as in latently-infected human lung, positive signals were also seen in bronchial epithelium, endothelial cells and fibroblasts from histologically-normal areas. Our results suggest that latent tuberculosis is induced and maintained by a type 1 cytokine pattern plus TNFalpha, and that mycobacteria persist intracellularly in lung tissue with and without histological evidence of a local immune response.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11985512      PMCID: PMC1906395          DOI: 10.1046/j.1365-2249.2002.01832.x

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  31 in total

1.  Exogenous reinfection in tuberculosis.

Authors:  P E Fine; P M Small
Journal:  N Engl J Med       Date:  1999-10-14       Impact factor: 91.245

2.  Exogenous reinfection as a cause of recurrent tuberculosis after curative treatment.

Authors:  A van Rie; R Warren; M Richardson; T C Victor; R P Gie; D A Enarson; N Beyers; P D van Helden
Journal:  N Engl J Med       Date:  1999-10-14       Impact factor: 91.245

Review 3.  Mechanisms of latency in Mycobacterium tuberculosis.

Authors:  N M Parrish; J D Dick; W R Bishai
Journal:  Trends Microbiol       Date:  1998-03       Impact factor: 17.079

Review 4.  Dormancy of Mycobacterium tuberculosis and latency of disease.

Authors:  L G Wayne
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1994-11       Impact factor: 3.267

5.  Analysis of the local kinetics and localization of interleukin-1 alpha, tumour necrosis factor-alpha and transforming growth factor-beta, during the course of experimental pulmonary tuberculosis.

Authors:  R Hernandez-Pando; H Orozco; K Arriaga; A Sampieri; J Larriva-Sahd; V Madrid-Marina
Journal:  Immunology       Date:  1997-04       Impact factor: 7.397

6.  Interactions between hormone-mediated and vaccine-mediated immunotherapy for pulmonary tuberculosis in BALB/c mice.

Authors:  R Hernandez-Pando; L Pavon; E H Orozco; J Rangel; G A Rook
Journal:  Immunology       Date:  2000-07       Impact factor: 7.397

7.  Increased production of interleukin 4 by CD4+ and CD8+ T cells from patients with tuberculosis is related to the presence of pulmonary cavities.

Authors:  R van Crevel; E Karyadi; F Preyers; M Leenders; B J Kullberg; R H Nelwan; J W van der Meer
Journal:  J Infect Dis       Date:  2000-03       Impact factor: 5.226

8.  Type 2 cytokine gene activation and its relationship to extent of disease in patients with tuberculosis.

Authors:  G T Seah; G M Scott; G A Rook
Journal:  J Infect Dis       Date:  2000-01       Impact factor: 5.226

9.  Correlation between the kinetics of Th1, Th2 cells and pathology in a murine model of experimental pulmonary tuberculosis.

Authors:  R Hernández-Pando; H Orozcoe; A Sampieri; L Pavón; C Velasquillo; J Larriva-Sahd; J M Alcocer; M V Madrid
Journal:  Immunology       Date:  1996-09       Impact factor: 7.397

10.  Growth of Mycobacterium tuberculosis in BCG-resistant and -susceptible mice: establishment of latency and reactivation.

Authors:  D H Brown; B A Miles; B S Zwilling
Journal:  Infect Immun       Date:  1995-06       Impact factor: 3.441

View more
  24 in total

1.  Immunological responses and protective immunity against tuberculosis conferred by vaccination of Balb/C mice with the attenuated Mycobacterium tuberculosis (phoP) SO2 strain.

Authors:  D Aguilar; E Infante; C Martin; E Gormley; B Gicquel; R Hernandez Pando
Journal:  Clin Exp Immunol       Date:  2007-02       Impact factor: 4.330

2.  Evaluation of the overall IFN-γ and IL-17 pro-inflammatory responses after DNA therapy of tuberculosis.

Authors:  Carlos R Zárate-Bladés; Rodrigo F Rodrigues; Patricia R M Souza; Wendy M Rios; Luana S Soares; Rogério S Rosada; Izaíra T Brandão; Ana Paula Masson; Elaine M Floriano; Simone G Ramos; Celio L Silva
Journal:  Hum Vaccin Immunother       Date:  2013-01-16       Impact factor: 3.452

3.  WhiB5, a transcriptional regulator that contributes to Mycobacterium tuberculosis virulence and reactivation.

Authors:  Stefano Casonato; Axel Cervantes Sánchez; Hirohito Haruki; Monica Rengifo González; Roberta Provvedi; Elisa Dainese; Thomas Jaouen; Susanne Gola; Estela Bini; Miguel Vicente; Kai Johnsson; Daniela Ghisotti; Giorgio Palù; Rogelio Hernández-Pando; Riccardo Manganelli
Journal:  Infect Immun       Date:  2012-06-25       Impact factor: 3.441

Review 4.  Reactive nitrogen species in host-bacterial interactions.

Authors:  Ferric C Fang; Andrés Vázquez-Torres
Journal:  Curr Opin Immunol       Date:  2019-06-12       Impact factor: 7.486

5.  Immunogenicity of eight dormancy regulon-encoded proteins of Mycobacterium tuberculosis in DNA-vaccinated and tuberculosis-infected mice.

Authors:  Virginie Roupie; Marta Romano; Lei Zhang; Hannelie Korf; May Young Lin; Kees L M C Franken; Tom H M Ottenhoff; Michèl R Klein; Kris Huygen
Journal:  Infect Immun       Date:  2006-12-04       Impact factor: 3.441

Review 6.  Mycobacterium tuberculosis infection of the 'non-classical immune cell'.

Authors:  Philippa J Randall; Nai-Jen Hsu; Valerie Quesniaux; Bernhard Ryffel; Muazzam Jacobs
Journal:  Immunol Cell Biol       Date:  2015-03-24       Impact factor: 5.126

7.  Kinetics and cellular sources of cathelicidin during the course of experimental latent tuberculous infection and progressive pulmonary tuberculosis.

Authors:  J Castañeda-Delgado; R Hernández-Pando; C J Serrano; D Aguilar-León; J León-Contreras; C Rivas-Santiago; R Méndez; I González-Curiel; A Enciso-Moreno; B Rivas-Santiago
Journal:  Clin Exp Immunol       Date:  2010-09       Impact factor: 4.330

8.  Immunotherapeutic effects of recombinant adenovirus encoding granulocyte-macrophage colony-stimulating factor in experimental pulmonary tuberculosis.

Authors:  A Francisco-Cruz; D Mata-Espinosa; S Estrada-Parra; Z Xing; R Hernández-Pando
Journal:  Clin Exp Immunol       Date:  2013-03       Impact factor: 4.330

9.  Proteins of the Rpf family: immune cell reactivity and vaccination efficacy against tuberculosis in mice.

Authors:  Vladimir V Yeremeev; Tatiana K Kondratieva; Elvira I Rubakova; Svetlana N Petrovskaya; Konstantin A Kazarian; Miroslav V Telkov; Sergej F Biketov; Arseny S Kaprelyants; Alexander S Apt
Journal:  Infect Immun       Date:  2003-08       Impact factor: 3.441

10.  Short-course therapy with daily rifapentine in a murine model of latent tuberculosis infection.

Authors:  Tianyu Zhang; Ming Zhang; Ian M Rosenthal; Jacques H Grosset; Eric L Nuermberger
Journal:  Am J Respir Crit Care Med       Date:  2009-09-03       Impact factor: 21.405

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.